美国 · 平台与数据 · MarketBeat

Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study

来源：MarketBeat · 美国 2 小时前

Oruka Therapeutics (NASDAQ:ORKA) reported interim week 16 results from EVERLAST-B, a Phase IIb dose-ranging study of ORKA-001 in adults with moderate-to-severe plaque psoriasis.…

在 MarketBeat 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.marketbeat.com)

Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study

推荐阅读

Is a Stock Market Crash Coming? What History Says a $10,000 Investment in an S&P 500 ETF Could Be Worth at the End of 2027.

Brixmor Property raises dividend by 7.3% to $0.33 a share

MSCI general counsel Robert Gutowski sells $1.48M in stock

What gave this city its ‘best place to retire’ crown? You can actually afford to live there.

Banks are locking AI agents out, Hashgraph CIO Gregg Bell says blockchain is the way back in

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study

分享

推荐阅读

Is a Stock Market Crash Coming? What History Says a $10,000 Investment in an S&P 500 ETF Could Be Worth at the End of 2027.

Brixmor Property raises dividend by 7.3% to $0.33 a share

MSCI general counsel Robert Gutowski sells $1.48M in stock

What gave this city its ‘best place to retire’ crown? You can actually afford to live there.

Banks are locking AI agents out, Hashgraph CIO Gregg Bell says blockchain is the way back in

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030